Free Trial

BioCardia (BCDA) Stock Price, News & Analysis

0.00 (0.00%)
(As of 07/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
12,560 shs
Average Volume
78,743 shs
Market Capitalization
$5.17 million
P/E Ratio
Dividend Yield
Price Target

BioCardia MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
2,012.7% Upside
$60.00 Price Target
Short Interest
3.72% of Float Sold Short
Dividend Strength
News Sentiment
0.00mentions of BioCardia in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$8,278 Bought Last Quarter
Proj. Earnings Growth
From ($6.30) to ($7.35) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.84 out of 5 stars

BCDA stock logo

About BioCardia Stock (NASDAQ:BCDA)

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.

BCDA Stock Price History

BCDA Stock News Headlines

Fed's New Power to Seize Bank Accounts
For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account.
BioCardia Announces Reverse Stock Split
BioCardia, Inc. (BCDA)
Fed's New Power to Seize Bank Accounts
For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account.
See More Headlines
Receive BCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Pharmaceutical Products
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
($1.11) per share


Free Float
Market Cap
$5.17 million
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

BCDA Stock Analysis - Frequently Asked Questions

How have BCDA shares performed this year?

BioCardia's stock was trading at $9.9630 on January 1st, 2024. Since then, BCDA stock has decreased by 71.5% and is now trading at $2.84.
View the best growth stocks for 2024 here

How were BioCardia's earnings last quarter?

BioCardia, Inc. (NASDAQ:BCDA) released its quarterly earnings results on Tuesday, May, 14th. The company reported ($1.35) EPS for the quarter. The company had revenue of $0.06 million for the quarter. BioCardia had a negative trailing twelve-month return on equity of 3,638.68% and a negative net margin of 2,208.76%.

When did BioCardia's stock split?

Shares of BioCardia reverse split on the morning of Thursday, May 30th 2024. The 1-15 reverse split was announced on Thursday, May 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did BioCardia IPO?

BioCardia (BCDA) raised $51 million in an IPO on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

How do I buy shares of BioCardia?

Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BioCardia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK) and Aurcana Silver (AUNFF).

This page (NASDAQ:BCDA) was last updated on 7/25/2024 by Staff

From Our Partners